Jinsy Andrews, MD, MSc

Academic Appointments

  • Associate Professor of Neurology

Current Administrative Positions

  • Director of Neuromuscular Clinical Trials
Jinsy Andrews, MD, MSc

Jinsy A. Andrews, M.D., M.Sc., FAAN is an Associate Professor of Neurology, in the Division of Neuromuscular Medicine and serves as the Director of Neuromuscular Clinical Trials. She currently oversees neuromuscular clinical trials and cares for patients with neuromuscular disease, primarily with Amyotrophic Lateral Sclerosis (ALS). Dr. Andrews has extensive experience in all phases of human clinical trials and drug development in both the academic and industry settings. Dr. Andrews is the elected co-chair of the Northeastern ALS (NEALS) Consortium, which is a network of over 100 ALS clinical research centers internationally. She is also elected to the National Board of Trustees of the ALS Association and is a Fellow of the American Academy of Neurology (FAAN). Dr. Andrews has also received the Diamond Award for ALS clinical research from Wings Over Wall Street and the Muscular Dystrophy Association.

Dr. Andrews received her B.S. from Union College, M.Sc. in Biostatistics (Patient-Oriented Research) from Columbia University's Mailman School of Public Health and M.D. from Albany Medical College. She completed her residency training in Neurology at the University of Connecticut and served as the Chief Neurology Resident in her final year. Dr. Andrews completed fellowship training in Neuromuscular Disease/ALS and Clinical Neurophysiology at Columbia University. She is board certified in Neurology, Neuromuscular Disease, and Electrodiagnostic Medicine.

Departmental Appointments

  • Department of Neurology
    Division of Neuromuscular Medicine

Board Certifications

  • Neurology
  • Neuromuscular Medicine

Areas of Expertise

  • Neuromuscular Disease
  • Neuromuscular Disorder

Education and Training

  • MD, 2001 Albany Medical College
  • Internship: University of Connecticut Health Center
  • Residency: 2005 Hartford Hospital
  • Fellowship: NewYork-Presbyterian/Columbia
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Locations

  • CUMC/Neurological Institute of New York

    710 West 168th Street
    New York, NY 10032
    For new and current patient appointments, call:
    (212) 305-1319
    Fax:
    (212) 305-1304

Provider Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • AETNA [Aetna Signature Administrators, EPO, HMO, Medicare Managed Care, NYP Employee Plan, NY Signature, POS, PPO, Student Health]
  • Affinity Health Plan [Essential Plan, Medicaid Managed Care]
  • AgeWell [Medicare Managed Care, Special Needs]
  • Amida Care [Special Needs]
  • Capital District Physician Health Plan [Capital District Physician Health Plan]
  • CIGNA [EPO, Great West (National), HMO, POS, PPO]
  • Emblem/GHI [Medicare Managed Care, PPO]
  • Empire Blue Cross/Blue Shield [EPO, Medicare Managed Care, PPO]
  • Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
  • Health First [Child/Family Health Plus, Leaf (Exchange), Medicaid Managed Care, Medicare Managed Care]
  • Health Insurance Plan of NY (HIP) [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
  • Health Plus - Amerigroup [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
  • Local 1199 [Local 1199]
  • MagnaCare (National) [MagnaCare]
  • Medicare [Traditional Medicare]
  • Multiplan [Multiplan]
  • MVP Health Care [Child/Family Health Plus, Essential Plan, HMO, Medicaid Managed Care]
  • Oxford Health Plans [Freedom, Liberty]
  • United Health Care [Columbia Employee POS, Compass (Exchange), HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
  • VNSNY CHOICE SelectHealth [Medicare Managed Care, Select Health, Special Needs]
  • WellCare [Medicaid Managed Care, Medicare Managed Care]

This provider accepts new patients

Appointment Phone Number: 212-305-6788

Lab Locations

  • CUMC/Neurological Institute of New York

    710 West 168th Street
    New York, NY 10032

NIH Grants

  • EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS: OPEN-LABEL EXTENSION FOR PATIENTS COMPLETING STUDY 3119002 (P&S Industry Clinical Trial)

    Jan 13 2020 - Jan 13 2025

    ANOPEN-LABEL, ADAPTIVE DESIGN STUDY IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) TO CHARACTERIZE SAFETY, TOLERABILITY AND BRAIN MICROGLIA RESPONSE, AS MEASURED BY TSPO BINDING, FOLLOWING MULTIPLE DOSES OF (P&S Industry Clinical Trial)

    Dec 12 2019 - Dec 12 2024

    APROSPECTIVE, MULTI-CENTER, OBSERVATIONAL STUDY OF THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF SPINRAZA IN ADULT PATIENTS WITH SPINAL MUSCULAR ATROPHY (P&S Industry Clinical Trial)

    Nov 25 2019 - Nov 25 2024

    ASTUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS AND PHARMACODYNAMICS OF BIIB067 ADMINSTRED TO ADULTS WITH AMYOTROPHIC LATER SCLEROSIS AND CONFIRMED SUPEROXIDE DISMUTASE 1 MUTATIO (P&S Industry Clinical Trial)

    Sep 23 2019 - Sep 23 2024

    APHASE 1 MULTIPLE-ASCENDING-DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF BIIB078 ADMINISTERED INTRATHECALLY TO ADULTS WITH C9ORF72-ASSOCIATED AMYOTROPHIC LATERAL SCLEROSIS (P&S Industry Clinical Trial)

    Sep 24 2018 - Sep 24 2023

    EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS STUDY (P&S Industry Clinical Trial)

    Sep 7 2018 - Sep 7 2023

    ARANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY OF MANNAC IN SUBJECTS WITH GNE MYOPATHY (Federal Gov)

    May 1 2020 - Apr 30 2023

    AMULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF H.P. ACTHAR GEL IN THE TREATMENT OF SUBJECTS WITH AMYTROPHIC LATERAL SCLEROSIS. (P&S Industry Clinical Trial)

    Jan 26 2018 - Jan 26 2023

    APHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NP001 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND EVIDENCE OF ELEVATED SYSTEMIC INFLAMMATION (P&S Industry Clinical Trial)

    Feb 17 2017 - Feb 17 2022

    AN EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY TOLERABILITY PHAMRACOKINETICS AND EFFECT ON DISEASE PROGRESSION OF BIIB078 ADMINISTERED TO PREVIOUSLY TREATED ADULTS WIH C9ORF72 ASSOCIATED AMYOTROPHIC LATERAL SCLEROSIS (P&S Industry Clinical Trial)

    Jun 11 2020 - Nov 6 2020

    MULTICENTER ALS COHORT STUDY OF OXIDATIVE STRESS AND DISEASE PROGRESSION (Federal Gov)

    Jul 22 2009 - Apr 30 2016

    2008 WINGS OVER WALL STREET (Private)

    Jul 1 2009 - Jun 30 2011